LFSC F/m Emerald Life Sciences Innovation ETF

ETF on NASDAQ (US) · Actively managed · Listing

Form N-PORT Aug 31, 2026 vs May 31, 2026 Filed with the SEC Oct 30, 2026
Book +20% $105M → $126M
Line items (May 31, 2026: 40) 39
In top 10 54%
Largest holding: Travere Therapeutics, Inc. ($11.0M) 8.7%
Portfolio date Aug 31, 2026
New / increased 2 / 31
Reduced / closed 5 / 3
Unchanged 0
−32%

Most notable sale · Guardant Health, Inc.

Guardant Health, Inc. cut by 32%

Shares went from 44,694 to 30,287 ($5.80M → $4.82M). Now 3.8% of the portfolio. Estimated trade $2.29M.

+85%

Most notable buy · BillionToOne, Inc.

BillionToOne, Inc. raised by 85%

Shares went from 29,023 to 53,729 ($2.87M → $4.87M). Now 3.9% of the portfolio. Estimated trade $2.24M.

Largest holding: Travere Therapeutics, Inc., cut 3%, 165,892 shares ($11.0M).

Travere Therapeutics, Inc.: 8.7% Corcept Therapeutics Incorporated: 6.7% Spyre Therapeutics, Inc.: 6.7% LivaNova PLC: 6.6% Cogent Biosciences, Inc.: 6.5% Mirum Pharmaceuticals, Inc.: 4.3% BillionToOne, Inc.: 3.9% Guardant Health, Inc.: 3.8% Cytokinetics, Incorporated: 3.5% United Therapeutics Corporation: 3.3% The other 29 positions: 46.0% $126M Holdings value
Current positions Top 10 % of book
Travere Therapeutics, Inc. TVTX $11.0M · −3% sh 8.7%
Corcept Therapeutics Incorporated CORT $8.49M · +3% sh 6.7%
Spyre Therapeutics, Inc. SYRE $8.46M · +3% sh 6.7%
LivaNova PLC LIVN $8.35M · +3% sh 6.6%
Cogent Biosciences, Inc. COGT $8.18M · +3% sh 6.5%
Mirum Pharmaceuticals, Inc. MIRM $5.46M · +9% sh 4.3%
BillionToOne, Inc. BLLN $4.87M · +85% sh 3.9%
Guardant Health, Inc. GH $4.82M · −32% sh 3.8%
Cytokinetics, Incorporated CYTK $4.41M · +44% sh 3.5%
United Therapeutics Corporation UTHR $4.14M · +3% sh 3.3%

Slices are % of holdings value. Changes ("sh" shares, "units" other holdings) are in the quantity held against May 31, 2026.

Healthcare: 98.4% Technology: 1.2% Unclassified: 0.4% 2 sectors
Sectors % of holdings value
Healthcare 98.4%
Technology 1.2%
Unclassified 0.4%
Biotechnology: 69.0% Medical Devices: 16.2% Diagnostics & Research: 8.9% Medical Care Facilities: 3.0% Health Information Services: 1.3% Software - Application: 1.2% Unclassified: 0.4% 6 industries
Industries % of holdings value
Biotechnology 69.0%
Medical Devices 16.2%
Diagnostics & Research 8.9%
Medical Care Facilities 3.0%
Health Information Services 1.3%
Software - Application 1.2%
Unclassified 0.4%
Initiations 2 Value
Praxis Precision Medicines, Inc. PRAX 1.0% of portfolio $1.24M
Replimune Group, Inc. REPL 0.5% of portfolio $695K
Increases 31 Change
BillionToOne, Inc. BLLN $2.87M → $4.87M +85%
Cytokinetics, Incorporated CYTK $3.32M → $4.41M +44%
Axsome Therapeutics, Inc. AXSM $2.98M → $3.85M +52%
NeoGenomics, Inc. NEO $453K → $1.53M +99%
ICU Medical, Inc. ICUI $2.20M → $3.49M +24%
Alphatec Holdings, Inc. ATEC $600K → $1.40M +93%
Mirum Pharmaceuticals, Inc. MIRM $5.17M → $5.46M +9%
Corcept Therapeutics Incorporated CORT $5.03M → $8.49M +3%
Spyre Therapeutics, Inc. SYRE $6.73M → $8.46M +3%
LivaNova PLC LIVN $7.47M → $8.35M +3%
Cogent Biosciences, Inc. COGT $7.91M → $8.18M +3%
United Therapeutics Corporation UTHR $4.37M → $4.14M +3%
Reductions 5 Change
Guardant Health, Inc. GH $5.80M → $4.82M −32%
Trevi Therapeutics, Inc. TRVI $3.27M → $3.26M −15%
F/m Ultrashort Treasury Inflat RBIL $1.14M → $564K −50%
Travere Therapeutics, Inc. TVTX $8.05M → $11.0M −3%
Dianthus Therapeutics, Inc. DNTH $3.24M → $3.41M −7%
Terminations 3 Change
Xeris Biopharma Holdings, Inc. XERS was $1.28M −100%
BridgeBio Pharma, Inc. BBIO was $1.23M −100%
Integer Holdings Corporation ITGR was $1.20M −100%

Source: the fund's quarterly portfolio reports to the SEC, the portfolio of Aug 31, 2026 (Form N-PORT) vs the portfolio of May 31, 2026 (Form N-PORT). Percent changes are changes in the quantity held (shares, or units for holdings that are not a listed equity); dollar values are as reported at each period end. Each column is ranked by the estimated dollar size of the trade: a new or closed position at its value, otherwise the change in shares at the position's own period-end price. Where shares and price per share moved by inverse whole multiples (a split), the earlier share count is restated. Cash and money-market lines are in the book and its value but are never counted as trades. Short positions are listed as such, at their (negative) printed value.

Objective

The investment objective of the F/m Emerald Life Sciences Innovation ETF (the "Fund") is to seek long-term capital appreciation.

Principal investment strategies

The Fund is an actively managed exchange-traded fund ("ETF") and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust (the "Sub-Adviser"), the Fund's investment sub-adviser, under the supervision of the Adviser. The Fund intends to identify and invest in unique growth opportunities within the life sciences universe by following scientific, technological and/or strategic innovation. The Sub-Adviser believes that innovative companies are those developing new products or reinventing/redesigning existing products/services, thereby generating value for their customers, creating a competitive advantage and/or driving business growth. The Sub-Adviser applies this theme of innovation by using its proprietary 10-step research process to identify companies that the Sub-Adviser believes are substantially focused on or are expected to substantially benefit from one or more of the following criteria: ● Technological Advancement: In its simplest terms, technological advancement in life science companies involves the translation of innovative science into new products and/or services that improve the lives of consumers. ● Market Disruption: Market disruption occurs when a company uses new or enhanced technology, manufacturing, marketing, distribution or service delivery approaches to challenge conventional business models, markets, or industries. ● Artificial Intelligence (AI) in life science: AI plays a key role in many areas within the Life Sciences industry, utilized by companies that build new AI products and those that most effectively use AI to enhance their business. The Sub-Adviser intends to apply the above principles to the following life science fields, among others: Biotechnology. Biotechnology companies translate innovative science into therapeutic applications. This is done by a variety of treatment modalities including small molecules, antibodies, nucleic acids, or a combination of several of these treatment modalities. Pharmaceutical. Pharmaceutical companies develop, produce and distribute medications. Medical Diagnostics. Medical Diagnostic companies play a vital role in diagnosing and monitoring medical conditions. These can be an imaging test using an X-Ray, CT, MRI etc. or a laboratory performed test on a sample, among others. Molecular Diagnostic tests are used to help identify a disease or the risk of developing a disease, such as cancer, by studying molecules, such as DNA, RNA, and proteins, in a tissue or fluid sample. Molecular diagnostics may also be used to help plan the treatment for a disease, look for recurrence of a disease, or find out how well a treatment is working. This can take the form of tests for specific biomarkers, genetic tests for predisposition to a disease or condition, tumor sequencing tests or liquid biopsy tests. Medical Devices. Medical devices companies produce instruments, apparatuses, or machines that are used in the prevention, diagnosis or treatment of illness or disease, or for detecting, measuring, restoring, correcting, or modifying the structure or function of the body for a health purpose. Healthcare Services. Healthcare services companies provide care and/or services in multiple settings, ranging from hospital services to urgent care clinics to newer modes of engagement with telemedicine. Healthcare Technologies ("Health-tech"). Health-tech companies incorporate novel technologies that enable the delivery of technology-enabled healthcare products and services that can be delivered or consumed outside of a hospital or physician's office or enhance overall outcomes through artificial intelligence or machine learning. Synthetic Biology. Synthetic Biology is a scientific field that uses engineering principles to design and modify organisms and biological systems.

Management and Contact

Adviser
Fm Investments LLC
Sub-adviser
Emerald Mutual Fund Advisers Trust
Phone
1-800-617-0004

Holdings as of Aug 31, 2026

39 lines, 38 linked, weights sum to 100.04% · Actively managed (N-CEN)

Holding Ticker / identifier Type Shares Change Weight Market value
Travere Therapeutics Inc TVTX US89422G1076 Equity 165,892 −4,822 8.71% $ 10.995M
Corcept Therapeutics Inc CORT US2183521028 Equity 74,897 +2,443 6.72% $ 8.49M
Spyre Therapeutics Inc SYRE US00773J2024 Equity 94,677 +3,089 6.70% $ 8.457M
LivaNova PLC LIVN GB00BYMT0J19 Equity 104,627 +3,415 6.61% $ 8.35M
Cogent Biosciences Inc COGT US19240Q2012 Equity 233,781 +7,639 6.48% $ 8.182M
Mirum Pharmaceuticals Inc MIRM US6047491013 Equity 55,641 +4,730 4.32% $ 5.456M
Billiontoone Inc BLLN US0901681058 Equity 53,729 +24,706 3.86% $ 4.872M
Guardant Health Inc GH US40131M1099 Equity 30,287 −14,407 3.81% $ 4.816M
Cytokinetics Inc CYTK US23282W6057 Equity 62,243 +18,975 3.50% $ 4.414M
United Therapeutics Corp UTHR US91307C1027 Equity 8,102 +261 3.27% $ 4.135M
Axsome Therapeutics Inc AXSM US05464T1043 Equity 19,398 +6,675 3.05% $ 3.851M
Nektar Therapeutics NKTR US6402683063 Equity 52,589 +1,713 2.97% $ 3.754M
TransMedics Group Inc TMDX US89377M1099 Equity 43,305 +1,411 2.91% $ 3.675M
Savara Inc SVRA US8051111016 Equity 673,019 +21,995 2.87% $ 3.628M
VeraDermics Inc MANE US9229671048 Equity 36,765 +1,197 2.87% $ 3.618M
ICU Medical Inc ICUI US44930G1076 Equity 20,198 +3,971 2.77% $ 3.493M
Dianthus Therapeutics Inc DNTH US2528281080 Equity 32,291 −2,593 2.70% $ 3.41M
Trevi Therapeutics Inc TRVI US89532M1018 Equity 196,667 −34,935 2.59% $ 3.265M
Viridian Therapeutics Inc VRDN US92790C1045 Equity 137,759 +4,498 2.53% $ 3.19M
Palvella Therapeutics Inc PVLA US6979471090 Equity 17,830 +576 2.15% $ 2.721M
Twist Bioscience Corp TWST US90184D1000 Equity 18,448 +598 2.03% $ 2.564M
Corvus Pharmaceuticals Inc CRVS US2210151005 Equity 170,887 +5,582 1.90% $ 2.399M
Ceribell Inc CBLL US15678C1027 Equity 91,335 +2,981 1.73% $ 2.19M
Hinge Health Inc HNGE US4333131039 Equity 18,179 +589 1.33% $ 1.683M
NeoGenomics Inc NEO US64049M2098 Equity 85,594 +42,523 1.21% $ 1.533M
Waystar Holding Corp WAY US9467841055 Equity 57,012 +1,857 1.18% $ 1.493M
Aveanna Healthcare Holdings In AVAH US05356F1057 Equity 109,347 +3,568 1.16% $ 1.467M
Alphatec Holdings Inc ATEC US02081G2012 Equity 149,732 +72,346 1.11% $ 1.403M
Globus Medical Inc GMED US3795772082 Equity 16,802 +544 1.08% $ 1.367M
Praxis Precision Medicines Inc PRAX US74006W2070 Equity 3,548 new +3,548 0.98% $ 1.243M
RadNet Inc RDNT US7504911022 Equity 15,398 +499 0.92% $ 1.167M
Lumexa Imaging Holdings Inc LMRI US5502491062 Equity 98,183 +3,206 0.91% $ 1.146M
Korro Bio Inc KRRO US5009461089 Equity 64,974 +2,119 0.64% $ 811.525K
Wave Life Sciences Inc WVE US94352A1043 Equity 157,141 +5,133 0.61% $ 769.991K
Insmed Inc INSM US4576693075 Equity 6,248 +198 0.60% $ 761.131K
Replimune Group Inc REPL US76029N1063 Equity 45,400 new +45,400 0.55% $ 694.62K
F/m Ultrashort Treasury Inflat RBIL US74933W2136 Fund 11,287 −11,464 0.45% $ 564.011K
Alamar Biosciences Inc ALMR US0109111056 Equity 9,757 +315 0.24% $ 297.979K
U.S. Bank Money Market Deposit Account
USBFS04 8AMMF0A92 Money market 571.8 +368.89 0.00% $ 571.80

Trades May 31, 2026 to Aug 31, 2026

Holding Ticker Action Before After Change Value
Guardant Health Inc GH Sold 44,694 30,287 −14,407 $ -2.291M
Billiontoone Inc BLLN Bought 29,023 53,729 +24,706 $ 2.24M
Cytokinetics Inc CYTK Bought 43,268 62,243 +18,975 $ 1.346M
Axsome Therapeutics Inc AXSM Bought 12,723 19,398 +6,675 $ 1.325M
Xeris Biopharma Holdings Inc XERS Closed 207,543 — −207,543 $ -1.278M
Praxis Precision Medicines Inc PRAX New — 3,548 +3,548 $ 1.243M
Bridgebio Pharma Inc BBIO Closed 18,534 — −18,534 $ -1.228M
Integer Holdings Corp ITGR Closed 13,436 — −13,436 $ -1.201M
NeoGenomics Inc NEO Bought 43,071 85,594 +42,523 $ 761.587K
Replimune Group Inc REPL New — 45,400 +45,400 $ 694.62K
ICU Medical Inc ICUI Bought 16,227 20,198 +3,971 $ 686.784K
Alphatec Holdings Inc ATEC Bought 77,386 149,732 +72,346 $ 677.882K
Trevi Therapeutics Inc TRVI Sold 231,602 196,667 −34,935 $ -579.921K
F/m Ultrashort Treasury Inflat RBIL Sold 22,751 11,287 −11,464 $ -572.856K
Mirum Pharmaceuticals Inc MIRM Bought 50,911 55,641 +4,730 $ 463.777K
Travere Therapeutics Inc TVTX Sold 170,714 165,892 −4,822 $ -319.602K
Corcept Therapeutics Inc CORT Bought 72,454 74,897 +2,443 $ 276.914K
Spyre Therapeutics Inc SYRE Bought 91,588 94,677 +3,089 $ 275.94K
Dianthus Therapeutics Inc DNTH Sold 34,884 32,291 −2,593 $ -273.847K
LivaNova PLC LIVN Bought 101,212 104,627 +3,415 $ 272.551K
Cogent Biosciences Inc COGT Bought 226,142 233,781 +7,639 $ 267.365K
United Therapeutics Corp UTHR Bought 7,841 8,102 +261 $ 133.209K
Nektar Therapeutics NKTR Bought 50,876 52,589 +1,713 $ 122.274K
TransMedics Group Inc TMDX Bought 41,894 43,305 +1,411 $ 119.752K
Savara Inc SVRA Bought 651,024 673,019 +21,995 $ 118.553K
VeraDermics Inc MANE Bought 35,568 36,765 +1,197 $ 117.797K
Viridian Therapeutics Inc VRDN Bought 133,261 137,759 +4,498 $ 104.174K
Palvella Therapeutics Inc PVLA Bought 17,254 17,830 +576 $ 87.892K
Twist Bioscience Corp TWST Bought 17,850 18,448 +598 $ 83.122K
Corvus Pharmaceuticals Inc CRVS Bought 165,305 170,887 +5,582 $ 78.371K
Ceribell Inc CBLL Bought 88,354 91,335 +2,981 $ 71.484K
Hinge Health Inc HNGE Bought 17,590 18,179 +589 $ 54.518K
Waystar Holding Corp WAY Bought 55,155 57,012 +1,857 $ 48.616K
Aveanna Healthcare Holdings In AVAH Bought 105,779 109,347 +3,568 $ 47.883K
Globus Medical Inc GMED Bought 16,258 16,802 +544 $ 44.265K
RadNet Inc RDNT Bought 14,899 15,398 +499 $ 37.834K
Lumexa Imaging Holdings Inc LMRI Bought 94,977 98,183 +3,206 $ 37.414K
Korro Bio Inc KRRO Bought 62,855 64,974 +2,119 $ 26.466K
Wave Life Sciences Inc WVE Bought 152,008 157,141 +5,133 $ 25.152K
Insmed Inc INSM Bought 6,050 6,248 +198 $ 24.12K
Alamar Biosciences Inc ALMR Bought 9,442 9,757 +315 $ 9,620.10

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up